TipRanks

Perceptive Advisors Llc Insider Profile

116 Followers
Perceptive Advisors Llc, Director at Immatics, holds 2.64M shares in LeonaBio (Ticker: LONA), holds 11.25M shares in Immatics (Ticker: IMTX), holds 10.87M shares in Freenome Inc (Ticker: FRNM).
tipranks
Perceptive Advisors Llc

Perceptive Advisors Llc
Immatics (IMTX)
Director

Ranked #280 out of 109,349 Corporate Insiders

Profitable Transactions

45%
87 out of 193 Profitable Transactions

Average Return

+20.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$810M
19.23%
17.25%
12.92%
12.18%
38.43% Others
A breakdown of Perceptive Advisors Llc's holdings

Insider Roles

ADMA Biologics
(ADMA)
Ten Percent Owner
Freenome Inc
(FRNM)
Ten Percent Owner
Meiragtx Holdings
(MGTX)
Director, Ten Percent Owner
Yarrow Bioscience
(YARW)
Ten Percent Owner
+15 other positions
Roles that Perceptive Advisors Llc holds in companies

Most Profitable Insider Trade

Stock:
Soleno Therapeutics
(SLNO)
Rating:Informative Buy
Date:Jun 06, 2023 - Jun 06, 2024
Return:+694.30%
The most profitable trade made by Perceptive Advisors Llc

Perceptive Advisors Llc's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Immatics
Aug 27, 2026
Director
Informative Buy
7.50M
$82.21M
Freenome Inc
Jul 22, 2026
Ten Percent Owner
Uninformative Buy
55.00M
$139.81M
FOLD
Amicus
Oct 05, 2018
―
Informative Buy
629.70K
$300.30M
ARAV
Aravive
Sep 25, 2017
―
Informative Sell
7.00M
$151.90K
CORI
Corium
Oct 15, 2018
―
Informative Sell
45.46M
$34.55M
ZGNX
Zogenix
Aug 14, 2018
―
Informative Buy
5.20M
$108.60M
QTNTQ
Quotient
Nov 02, 2022
―
Informative Sell
660.45K
$309.86K
GBT
Global Blood Therapeutics
Dec 19, 2017
―
Informative Buy
6.65M
$334.85M
ALBO
Albireo Pharma
Oct 13, 2022
―
Informative Sell
9.51M
$85.64M
Solid Biosciences
Feb 21, 2025
Director, Ten Percent Owner
Informative Buy
20.15M
$76.08M
LJPC
La Jolla Pharma
Jan 09, 2019
―
Informative Sell
11.72M
$14.02M
Motus Gi Holdings
Jan 22, 2021
Ten Percent Owner
Informative Sell
2.53M
$26.61K
DOVA
Dova Pharmaceuticals
Nov 15, 2019
―
Uninformative Sell
―
$0.00
Meiragtx Holdings
Apr 23, 2026
Director, Ten Percent Owner
Uninformative Buy
5.00M
$104.68M
AGRX
Agile Therapeutics
Oct 15, 2021
―
Informative Buy
4.87M
$32.70M
Verrica Pharmaceuticals
Dec 29, 2023
Ten Percent Owner
Informative Buy
2.31M
$24.28M
ATNXQ
Athenex
Sep 14, 2020
―
Informative Buy
22.05M
$202.99K
ADMA Biologics
Sep 30, 2021
Ten Percent Owner
Informative Sell
299.24K
$155.83M
KDMN
Kadmon Holdings
Nov 18, 2019
―
Informative Buy
5.00M
$139.05M
CRNX
Crinetics Pharmaceuticals
Apr 18, 2022
―
Informative Buy
3.50M
$452.02M
Lyra Therapeutics
Nov 13, 2025
Ten Percent Owner
Informative Sell
182.41K
$2.66K
Yarrow Bioscience
Aug 18, 2021
Ten Percent Owner
Informative Sell
435.00K
$98.70M
Cypherpunk Technologies
Jun 24, 2020
Ten Percent Owner
Informative Buy
3.50M
$28.06M
LeonaBio
Oct 26, 2026
Director, Ten Percent Owner
Uninformative Buy
3.76M
$12.94M
CERE
Cerevel Therapeutics Holdings
Feb 21, 2024
―
Uninformative Sell
―
$485.34M
ATXS
Astria Therapeutics
Feb 05, 2024
―
Informative Buy
30.00M
$81.59M
LABP
Landos Biopharma
Feb 09, 2021
―
Informative Buy
3.21M
$411.84M
RXDX
Prometheus Biosciences
Mar 16, 2021
―
Informative Buy
16.15M
$662.54M
~RAIN
Rain Oncology
Oct 13, 2021
―
Informative Sell
667.48K
$3.01M
Nautilus Biotechnolgy
Dec 10, 2021
Director, Ten Percent Owner
Informative Buy
1.07M
$28.61M
ISO
IsoPlexis
Oct 14, 2021
―
Informative Buy
12.75M
$3.12M
LianBio Sponsored ADR
Feb 20, 2024
Director, Ten Percent Owner
Uninformative Buy
86.09K
$2.53M
SLNO
Soleno Therapeutics
Sep 28, 2023
―
Informative Buy
15.11M
$162.98M
CRGX
CARGO Therapeutics, Inc.
Nov 14, 2023
―
Uninformative Buy
―
$1.49M
Acrivon Therapeutics, Inc.
May 01, 2025
Ten Percent Owner
Informative Sell
1.02M
$5.46M
Adagio Medical Holdings
Feb 14, 2025
Director, Ten Percent Owner
Uninformative Buy
―
$849.39K
Orchestra BioMed Holdings
Aug 05, 2025
Ten Percent Owner
Informative Buy
1.93M
$32.23M
Talphera
Jun 21, 2017
Ten Percent Owner
Informative Sell
2.10M
$6.42M
Aldeyra Therapeutics
Apr 07, 2025
Ten Percent Owner
Informative Sell
4.83M
$3.87M
VBIVQ
VBI Vaccines
Apr 06, 2023
―
Informative Sell
1.48M
$414.41K
Heron Therapeutics
Jul 07, 2011
Ten Percent Owner
Informative Buy
―
$7.84M
AEGR
Aegerion
Sep 09, 2013
―
Informative Buy
5.00M
$5.56M
~RPRX
Repros
Mar 19, 2013
―
Informative Sell
25.25M
$544.42K
GEVA
Synageva
Nov 08, 2011
―
Uninformative Sell
―
―
List of latest transactions for each holding click on a transaction to see Perceptive Advisors Llc's performance on stock

Perceptive Advisors Llc insider profile FAQ

What is the percentage of profitable transactions made by Perceptive Advisors Llc?
The percentage of profitable transactions made by Perceptive Advisors Llc is 45%.
    What is the average return per transaction made by Perceptive Advisors Llc?
    The average return per transaction made by Perceptive Advisors Llc is 20.40%.
      What stocks does Perceptive Advisors Llc hold?
      Perceptive Advisors Llc holds: IMTX, FRNM, FOLD, ARAV, CORI, ZGNX, QTNTQ, GBT, ALBO, SLDB, LJPC, MOTS, DOVA, MGTX, AGRX, VRCA, ATNXQ, ADMA, KDMN, CRNX, LYRA, YARW, CYPH, LONA, CERE, ATXS, LABP, RXDX, ~RAIN, NAUT, ISO, LIANY, SLNO, CRGX, ACRV, ADGM, OBIO, TLPH, ALDX, VBIVQ, HRTX, AEGR, ~RPRX, GEVA stocks.
        What was Perceptive Advisors Llc’s latest transaction?
        Perceptive Advisors Llc latest transaction was an Uninformative Buy of $3.76M.
          What was Perceptive Advisors Llc's most profitable transaction?
          Perceptive Advisors Llc’s most profitable transaction was an Informative Buy of SLNO stock on June 6, 2023. The return on the trade was 694.30%.
            What is Perceptive Advisors Llc's role in Immatics?
            Perceptive Advisors Llc's role in Immatics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.